Trial Profile
An Open-Label, Multicenter, Twelve-Month Study of Safety and Tolerability in the Treatment of Schizophrenia
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 11 Aug 2023
Price :
$35
*
At a glance
- Drugs Lurasidone (Primary)
- Indications Schizophrenia
- Focus Adverse reactions
- Sponsors Sunovion Pharmaceuticals
- 26 Nov 2014 New trial record